Community-Acquired Pneumonia 2000-2015: What is New?

Catia Cillóniz, PhD and Antoni Torres, MD
Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain

ABSTRACT
Despite the development of new diagnostic tests, new antimicrobial agents, and the implementation of international guidelines in recent decades, community-acquired pneumonia still has high morbidity and mortality worldwide and is associated with moderate health costs. Streptococcus pneumoniae is still the most frequent pathogen related to microbial aetiology of community-acquired pneumonia, although almost 50% of cases of pneumonia still have no microbiological diagnosis. However, the development of molecular techniques such as real-time polymerase chain reaction in the past five years has revealed respiratory viruses to be major causative agents in community-acquired pneumonia. With the explosion of information from the many studies focusing on community-acquired pneumonia epidemiology, microbial aetiology and management in the last 15 years, the introduction of predictive tools, and advances in the pathophysiology of the disease, management of community-acquired pneumonia has also improved over this time due to the implementation of international guidelines proposed by different scientific associations. This review focuses on the new data in the management of community-acquired pneumonia.

Key words: Community acquired pneumonia. Management. Pneumonia.
INTRODUCTION

Despite the development of new diagnostic tests, new antimicrobial agents, and the implementation of international guidelines in recent decades, community-acquired pneumonia (CAP) still has high morbidity and mortality worldwide and is associated with moderate health costs.

There is consistent evidence that the incidence of CAP has risen in recent decades and the hospitalization rate has increased. However, there is no concrete explanation for this phenomenon. It is true that mortality related to CAP has declined over time in the general population. However, in patients with severe CAP, mortality rates remain as high as 35% in cases requiring admission to an intensive care unit (ICU).

Streptococcus pneumoniae (pneumococcus) remains the most frequent pathogen in CAP in all settings (outpatients, patients requiring hospitalization, and patients requiring ICU treatment), in all age groups, and regardless of comorbidity. The improvement of molecular diagnostic techniques in the last years has demonstrated the increasing prevalence of respiratory viruses in CAP. The Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak, the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic, and the 2009 H1N1 influenza pandemic are some examples of new viral pathogens involved in pneumonia.

Another important difficulty related to the management of CAP patients is the considerable problem with the emergence of antimicrobial resistance of common pathogens in CAP, especially multidrug-resistant pneumococcal clones and gram-negative bacilli.

Moreover, we know that the increased use of antibiotics generates resistance in microorganisms through adaptation to antibiotic pressure. Between 2000 and 2010, global antibiotic use increased by 36% from approximately 50 to 70 billion standard units, based on data from 71 countries, including most countries with large populations (Fig. 1).

This review focuses on the data published from 2000 to 2015 on the more important aspects of CAP.

EPIDEMIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA

World Health Organization (WHO) 2012 statistics indicate that lower respiratory tract infections (LRTI) are the fourth cause of death globally and the number one cause of death in low-income countries. In the USA, pneumonia was reported as the ninth most common cause of death in 2010. In 2013, The Global Burden of Disease Study reported that LRTI are the second cause of death; this report was based on data from 188 countries around the world. In Europe, mortality rates for CAP vary widely from country to country, ranging from < 1 to 48%.

In a comprehensive literature review, Torres et al. found the overall annual incidence of CAP in Europe to be between 1.07 and 1.2 per 1000 person-years and 1.54 and 1.7 per 1000 population. In the same review, the authors found that the incidence of CAP...
increased with age to 14 per 1000 person-years in adults aged ≥ 65 years and the incidence of CAP was significantly higher in men than in women¹² (Fig. 2).

The Etiology of Pneumonia in the Community (EPIC) study reported by Jain et al.⁶ found an increased incidence of pneumonia with increasing age; the annual incidence of pneumonia in the US was 24.8 cases per 10,000 adults, with the highest rates among adults 65-79 years of age (63.0 cases per 10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults).

The economic cost related to CAP remains high. A recently published Dutch study that included 195,372 CAP cases reported that the median costs of CAP case were dependent on age and type of care, with costs ranging from €344 (€482) per episode for 0-9 year olds treated as outpatients, to €10,284 (€16,374) per episode for 50-64 year olds admitted to the ICU¹³. Another major study that provides an overview of the importance of comorbidity conditions in the economic cost of pneumonia (Fig. 3) is the recently published study by Weycker et al.¹⁴ on the rates and cost of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.

Despite the implementation of important measures in recent decades, such as widespread
Figure 2. Overall CAP incidence* in Europe. Literature review in >15 y.o. patients, 60 Studies (Reproduced with permission from Torres A et al. Thorax: 2013;68:1057-65).

*All incidences reported as per 1000 Person Years.
CAP: community-acquired pneumonia.

Figure 3. Annual cost of all-cause pneumonia per 100,000 persons with risk conditions, by number of conditions, versus their healthy counterparts (reproduced with permission from BMC Journal).

*Risk condition: presence of medical condition.
use of pneumococcal conjugate vaccine and influenza vaccination, implementation of international guidelines that help in the use of appropriate antibiotic treatment and reducing length of hospital stay, the rate and cost for persons with risk conditions such as asthma and diabetes have increased in recent years.14

**RISK FACTORS**

In the past 15 years, several studies have reported specific risk factors for CAP.15,16

**Age**

Pneumonia can occur at any age, but its incidence increases significantly with advanced age. The EPIC study reported by Jain et al.6 found an increased incidence of pneumonia with increasing age; the annual incidence of pneumonia was 24.8 cases per 10,000 adults, with the highest rates among adults aged between 65 and 79 years (63.0 cases per 10,000 adults) and those aged 80 years or older (164.3 cases per 10,000 adults). Viral pneumonia is most frequent in middle-aged adults.17 However, the incidence is variable in immunocompetent adults and increases with epidemics and ageing.18

**Male sex**

A recently published article by Li et al.19 suggested that being male is an increased risk for increase hospital mortality in patients admitted to the ICU with pneumonia.

**Lifestyle factors and risk of community-acquired pneumonia**

Several case-control studies have demonstrated the association between lifestyle factors and the risk of CAP.15

- Exposure to cigarette smoke was associated with an increased risk of CAP. Smoking is associated with colonization by pathogenic bacteria and an increased risk of lung infections, especially in the case of *S. pneumoniae*.20

- Higher consumption of alcohol (≥ 80 g/l) is a risk factor for CAP. Samokhvalo et al.21 performed a meta-analysis that showed that the consumption of 24, 60, and 120 g of pure alcohol daily resulted in a relative risk for CAP incidents of 1.12 (95% CI: 1.02-1.23), 1.33 (95% CI: 1.06-1.67), and 1.76 (95% CI: 1.13-2.77), respectively, relative to non-drinkers.

- Being underweight is associated with increased risk of CAP, so it is reported that obese patients with pneumonia have lower mortality compared to normal weight patients.12

- Living conditions: living in a household of more than 10 people, regular contact with children, higher levels of education, and good dental hygiene were associated with reduced risk of CAP.12,16

**Specific comorbidities and risk of community-acquired pneumonia**

- Patients with chronic respiratory diseases (including chronic obstructive pulmonary
disease [COPD], bronchitis and asthma) had a two- to fourfold to fourfold increase in the risk of CAP. In the case of COPD, a study by Restrepo et al.22 analysed 744 patients with CAP and reported that COPD patients with CAP had a higher PSI score (105 ± 32 versus 87 ± 34) compared with patients without COPD; these patients were also admitted more frequently to the ICU (25 versus 18%). COPD patients with CAP exhibited higher 30-day and 90-day mortality than patients without COPD. Some studies suggested that the use of inhaled corticosteroids usually administered in COPD and asthma patients may increase the risk of CAP23,24. However, despite the risk of CAP observed, many studies reported that prior use of inhaled corticosteroids reduced CAP mortality in COPD patients25.

- Chronic cardiovascular disease increased the risk of CAP up to threefold15.
- Cerebrovascular disease/stroke and dementia approximately doubled the risk of CAP26.
- Diabetes mellitus was associated with a moderate increase in the risk of CAP27.
- Chronic liver or renal disease increased the risk of CAP approximately twofold15.
- Hospitalization in the previous five years was associated with an increased risk of CAP16.
- Immunosuppression: human-immunodeficiency virus (HIV) infection, asplenia28.

Genetic Factors

New studies have revealed that host genetic susceptibility is a risk factor for CAP. Some studies suggest that specific mutations or polymorphisms play an important role in the variable immune response to CAP. The innate immune system is crucial to host defences against pathogenic microorganisms. Toll-like receptors (TLR) are proteins that recognize bacterial pathogens.

- Toll-like receptor 4 (TLR4) A299G polymorphism. The results of a recently published meta-analysis29 suggest that susceptibility to pneumonia is associated with TLR4 A299G polymorphism.
- TLR6 polymorphism is associated with increased risk of Legionnaires’ disease30.

Other risk factors

The use of proton pump inhibitors also has been reported as an additional risk factor for CAP31. A recent systematic review and meta-analysis of the risk of CAP with outpatient proton pump inhibitor therapy found the risk of CAP increased 1.5-fold in outpatients using proton pump inhibitor therapy32.

CAUSATIVE PATHOGENS

Several studies on the microbial aetiology of CAP have been published in the past 15 years6,33. Some of them showed that microbial causes of CAP differ according to the severity of disease at clinical presentation34 (Table 1).

*Streptococcus pneumoniae* (pneumococcus) remains the most frequent pathogen in CAP. However, its incidence is decreasingly reported due to several factors including the
introduction of polysaccharide vaccine PCV7 and PCV13 and the decreased rate of smoking in countries such as the USA\textsuperscript{35}. An estimated prevalence of 19.3-27.9\% was reported for \textit{S. pneumoniae} in Europe\textsuperscript{36}. Furthermore, pneumococcus was observed less frequently in CAP cases treated in the community than in cases treated in the hospital or ICU. Intracellular pathogens (\textit{Mycoplasma pneumoniae}, \textit{Legionella pneumophila}, \textit{Chlamydia pneumoniae}, \textit{Chlamydia psittaci}, and \textit{Coxiella burnetii}), together with pneumococcus, are the most frequently reported pathogens causing CAP in both outpatients and hospitalized patients\textsuperscript{33}. A study by Arnold et al.\textsuperscript{37} reported a 20\% incidence of intracellular pathogens in CAP patients. Intracellular pathogens sometimes appear to cause more severe disease with respiratory failure and multisystem dysfunction associated with fatal outcomes. These microorganisms may cause severe CAP in approximately 1-7\% of cases\textsuperscript{33}.

Respiratory viruses are also a common cause of CAP and account for 7-36\% of cases with defined microbial aetiology\textsuperscript{6,38}. The incidence of respiratory viruses varies with seasonality, geographic location, and age group. A good example of this is the recently published study by Jain et al.\textsuperscript{6} on CAP in hospitalized adult patients, where the three principal pathogens reported in this study were rhinovirus (9\%), influenza virus (6\%), and \textit{S. pneumoniae} (5\%). It is known that seasonal influenza virus and respiratory syncytial virus cause pneumonia in very young and very old patients\textsuperscript{39}. However, pandemic viruses affect mostly children and younger adults\textsuperscript{40}.

\begin{table}
\centering
\caption{Microbial aetiology of community-acquired pneumonia}
\begin{tabular}{|l|c|c|c|c|}
\hline
& \textbf{Outpatients} & \textbf{Hospitalized (non-ICU)} & \textbf{ICU patients} & \\
& \textit{Frequency} & \textit{Frequency} & \textit{Frequency} & \\
& \textbf{\%)} & \textbf{\%)} & \textbf{\%)} & \\
\hline
\textit{Streptococcus pneumoniae} & 35 & 43 & 42 & \\
\textit{Atypical bacteria} & 36 & 16 & 14 & \\
\textit{Legionella pneumophila} & 6 & 8 & 8 & \\
\textit{Mycoplasma pneumoniae} & 17 & 3 & 2 & \\
\textit{Chlamydia pneumoniae} & 6 & 3 & 3 & \\
\textit{Coxiella burnetii} & 7 & 2 & 1 & \\
\textit{Respiratory viruses} & 9 & 12 & 4 & \\
\textit{Haemophilus influenzae} & 5 & 5 & 3 & \\
\textit{Polymicrobial aetiology} & 9 & 13 & 22 & \\
\textit{Pseudomonas aeruginosa} & 1 & 4 & 5 & \\
\textit{GNEB} & 1 & 2 & 1 & \\
\textit{Staphylococcus aureus} & 1 & 2 & 2 & \\
\hline
\end{tabular}
\end{table}

*The frequency is determined by the presence or absence of specific risk factors.\textsuperscript{9} GNEB: gram-negative enteric bacilli. (Reproduced with permission from World Health Organization (WHO). The top 10 causes of death. 2016).
Newer pathogens have been documented including human metapneumovirus (hMPV) in 2001\(^41\), and coronavirus responsible for SARS-CoV in 2002\(^42\). Human bocavirus discovered in 2005\(^43\) and, more recently, MERS-CoV described in 2012\(^44\), community-acquired methicillin-resistant \textit{Staphylococcus aureus} (CA-MRSA)\(^45\), and H1N1 pandemic influenza virus in 2009 have also become CAP pathogens relatively recently.

Antibiotic-resistant pathogens are a worldwide concern. Approximately 6\% of CAP cases are caused by multidrug-resistant (MDR) pathogens. \textit{(S. aureus} and \textit{P. aeruginosa} were most frequently isolated)\(^46\). In a European study of pathogens isolated from hospitalized patients with CAP, MDR pathogens were the cause of CAP in 3.3-7.6\% of patients in whom a pathogen was identified, with methicillin-resistant \textit{S. aureus} being the most common MDR pathogen\(^47\). The study by Prina et al.\(^46\) that analysed 1,519 patients with CAP who presented aetiological diagnosis, found that PES (\textit{Pseudomonas aeruginosa, Enterobacteriaceae extended spectrum \beta-lactamase-positive, and methicillin-resistant Staphylococcus aureus}) pathogen was identified in 6\% of the CAP cases. The study also found that PES pathogens are associated with increased risk of 30-day mortality (OR: 2.51; 95\% CI: 1.20-5.25; \(p = 0.015\)). This study proposed a score to assess the risk of pneumonia due to PES pathogens (Table 2).

Furthermore, \textit{S. pneumoniae}, the most common cause of CAP, has increased its resistance to several antibiotics (cephalosporins, macrolides and fluoroquinolones) worldwide in the last two decades\(^48\). Currently, 20-30\% of pneumococcus disease cases worldwide are MDR (resistant to more than three classes of antibiotics) (Fig. 4).

However, mortality rates related to antibiotic-resistant \textit{S. pneumoniae} have not increased due to interventions such as conjugated pneumococcal vaccine, which covers the serotypes that are most likely to express resistance\(^49\). A recent Spanish study\(^50\) compared clinical outcomes in hospitalized patients with and without macrolide-resistant pneumococcus and reported no evidence suggesting that patients hospitalized for macrolide-resistant \textit{S. pneumoniae} pneumonia were more severely ill on presentation or had worse clinical outcomes if they were treated with guideline-compliant versus noncompliant regimens.

Community acquired MRSA has become an important CAP pathogen. Community and hospital MRSA share a \textit{mecA} gene that confers universal methicillin and \textit{\beta-lactam resistance, but CA-MRSA presents broader antibiotic susceptibility than hospital MRSA. CA-MRSA carries the gene for the Panton-Valentine leukocidin (PVL) toxin, which causes leukocyte destruction and tissue necrosis\(^51\). \textit{Pseudomonas aeruginosa} is not a frequent pathogen in CAP\(^33\). However, several studies reported that

<table>
<thead>
<tr>
<th>TABLE 2. Score to assess the risk of pneumonia due to PES pathogens.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score to PES pathogen</td>
</tr>
<tr>
<td>-----------------------</td>
</tr>
<tr>
<td>Age &gt; 65 y</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Previous antibiotic use</td>
</tr>
<tr>
<td>Chronic respiratory disorder</td>
</tr>
<tr>
<td>Chronic renal disease</td>
</tr>
<tr>
<td>At Emergency</td>
</tr>
<tr>
<td>Consciousness impairment or aspiration evidence</td>
</tr>
<tr>
<td>Fever or shivers</td>
</tr>
</tbody>
</table>

PES: denotes \textit{Pseudomonas aeruginosa, Enterobacteriaceae Extended Spectrum \beta-lactamase (ESBL+), Staphylococcus aureus methyciline resistant (MRSA)}\(^56\).
in patients with severe CAP requiring ICU admission, *P. aeruginosa* was the cause in 1.8-8.3%, with a case/fatality rate of 50-100%\textsuperscript{5,52}. Prevalence of MDR *P. aeruginosa* is not well known in CAP. A study by Cilloniz et al.\textsuperscript{53} reported 1% of cases were caused by MDR *P. aeruginosa*. They identified the use of prior antibiotic treatment as the only risk factors associated with CAP caused by MDR *P. aeruginosa*.

More recently, the emergence of macrolide-resistant *M. pneumoniae* strains\textsuperscript{54}, principally in Asian countries\textsuperscript{55}, in some European countries\textsuperscript{56}, and in the US\textsuperscript{57} is becoming a global problem. However, the clinical significance of macrolide resistance of *M. pneumoniae* in CAP outcomes is still unknown.

**RISK FACTORS ASSOCIATED WITH SPECIFIC PATHOGENS IN COMMUNITY-ACQUIRED PNEUMONIA**

Several studies have identified specific risk factors for a number of pathogens in CAP cases (Table 3).

In the case of *S. pneumoniae*, the most frequent pathogen in CAP cases, one study recently described the risk factors for pneumonia due to fluoroquinolone-resistant *S. pneumoniae* as previous use of fluoroquinolones, current residence in a nursing home, nosocomial acquisition of pneumococcal infection, penicillin resistance, and COPD\textsuperscript{58}. In the US, the SENTRY study reported that the rate of...
fluoroquinolone resistance in 2011 was 1.2%\textsuperscript{59}, whereas, in 2012, a study involving European countries reported a rate of 5.2%\textsuperscript{60}. In Asia, in a period between 2008 and 2009, the rate reported was 2.4% of fluoroquinolone resistance strains\textsuperscript{61}.

Risk factors for \textit{S. aureus} include advanced age, underlying lung disease, and previous antibiotic use, whereas the two reported risk factors for methicillin-resistant \textit{S. aureus} were prior hospitalization in the previous 90 days and requiring admission to the ICU\textsuperscript{47}. Risk factors for CA-MRSA include a history of viral upper respiratory infection, smoking, recent hospitalization, and chronic pulmonary disease\textsuperscript{62}. Recognized high-risk groups for CA-MRSA carriage and infection are athletes, military personnel, detainees in jail or prison, and children in day care centres\textsuperscript{63}. Since, the household is a major community-acquired reservoir for CA-MRSA, spread beyond households established this pathogen in the communities\textsuperscript{64}.

For \textit{P. aeruginosa}, pulmonary comorbidity is the major risk factor. Recently, Cilloniz et al.\textsuperscript{53}, in a cohort of 2,023 patients with CAP, reported that 4% of cases were caused by \textit{P. aeruginosa}; risk factors related to this pathogen were male sex, chronic respiratory disease, C-reactive protein < 12.35 mg/dl, and PSI risk class IV-V. In the case of MDR \textit{P. aeruginosa} CAP, the only risk factor was prior antibiotic treatment.

### MICROBIOLOGICAL DIAGNOSIS

Initial antibiotic treatment of CAP is empiric in the majority of the cases. Determining the microbial aetiology of CAP is fundamental to ensuring appropriate antibiotic therapy, which is an important factor for reducing mortality\textsuperscript{65}. However, in 50% of cases of CAP, the microbial aetiology is unknown\textsuperscript{66}. International CAP guidelines\textsuperscript{66,67} recommend an optional microbiological diagnostic test in low-to-mild cases of CAP, which should be

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Risk factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{Streptococcus pneumoniae}</td>
<td>Dementia, seizure disorders, congestive heart failure, cerebrovascular disease, chronic obstructive pulmonary disease, HIV infection, black race, overcrowded living conditions, and smoking.</td>
</tr>
<tr>
<td>\textit{S. pneumoniae} resistant to (\beta)-lactam, macrolides and fluoroquinolones</td>
<td>Age &lt; 2 years or ≥ 65 years, receipt of (\beta)-lactam treatment within the previous 3 months, exposure to a child who attends a day care centre, alcoholism, medical comorbidity, and immunosuppression.</td>
</tr>
<tr>
<td>\textit{Staphylococcus aureus} Community-acquired methicillin-resistant \textit{S. aureus (CA-MRSA)}</td>
<td>Advanced age, underlying lung disease, and previous antibiotic use. Previous viral upper respiratory infection, tobacco use, recent hospitalization, chronic pulmonary disease.</td>
</tr>
<tr>
<td>\textit{Haemophilus influenzae}</td>
<td>Chronic obstructive pulmonary disease treated with antibiotics or oral steroids within the previous 3 months.</td>
</tr>
<tr>
<td>\textit{Pseudomonas aeruginosa}</td>
<td>Pulmonary comorbidity (bronchiectasis, use of systemic steroids, chronic obstructive pulmonary disease especially in patients with inhaled corticosteroids) is the major risk factor.</td>
</tr>
<tr>
<td>\textit{Legionella pneumophila}</td>
<td>Recent repair of domestic plumbing, use of hot tubs and whirlpool spas, renal and/or hepatic failure, diabetes, and malignancy.</td>
</tr>
</tbody>
</table>
selected as clinically indicated. Blood cultures, sputum staining, sputum culture, and urinary antigen testing for *Legionella* and pneumococcus should be carried out in patients with severe CAP.

Microbiological diagnosis of CAP continues to be based on respiratory samples or blood culture. The main problems with these conventional methods are the low yield and long turnaround time (48-72 hours) and the fact that previous antibiotic use affects microbiological results\(^6\). However, the most important application of these methods is the ability to determine antibiotic susceptibility patterns that will allow for selection of appropriate antimicrobial therapy.

The introduction of molecular diagnostic techniques (polymerase chain reaction [PCR] or multiplex PCR), which are based on DNA or RNA detection of bacteria and viruses, offers several advantages over conventional diagnosis of the microbial aetiology of CAP: they provide results in a short time, do not require viable bacteria, and antimicrobial therapy does not influence their results\(^6\). However, they need to be validated in clinical practice. Some studies recommended the application of molecular techniques together with conventional methods in order to increase the diagnostic yield of microbiological diagnosis of CAP\(^7\).

<table>
<thead>
<tr>
<th>Microbiological test</th>
<th>Outpatient</th>
<th>Inpatient low severity</th>
<th>Inpatient non-ICU moderate severity</th>
<th>Inpatients ICU high severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sputum culture</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pneumococcal urinary antigen test</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><em>Legionella</em> urinary antigen test</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Blood culture</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Invasive respiratory tract sample culture</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Others</td>
<td>None routinely</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

INTERNATIONAL GUIDELINES RECOMMENDATIONS FOR MICROBIOLOGICAL DIAGNOSTIC TESTS IN COMMUNITY-ACQUIRED PNEUMONIA (TABLE 4)

In outpatients, routine microbiological test are optional. Blood culture and sputum staining and culture are recommended in hospitalized patients and in severe CAP. Also, urinary antigen test for *pneumococcus* and *Legionella pneumophila* is recommended. There are some special situations were microbiological tests should be applied:

- Outpatients with failure of antibiotic therapy: sputum culture, urinary antigen test for *Legionella pneumonia* and *Streptococcus pneumoniae*.
- Positive urinary antigen test for *pneumococcus* or *Legionella*: sputum and blood culture for positive urinary antigen test for *pneumococcus* and sputum culture for positive urinary antigen test for *Legionella*.

- Severe obstructive lung disease: sputum culture.

- Pleural effusion: sputum and blood culture, urinary antigen test for *pneumococcus* and *Legionella*, pleural fluid culture.

- Cavitary infiltrates: sputum culture (bacteria, fungi and mycobacteria) and blood culture.

- Active alcoholism: sputum and blood culture, urinary antigen test for *pneumococcus* and *Legionella*.

- Severe CAP admitted to ICU: sputum and blood culture, urinary antigen test for *pneumococcus* and *Legionella*, tracheal aspirate or bronchoalveolar lavage culture; viral studies also are recommended in these patients.

- Epidemiological factors or specific risk factors suggesting pathogen: urinary antigen test for *Legionella* (Legionnaires’ disease), influenza test during influenza season.

**Biomarkers**

Inflammatory biomarkers have been extensively investigated as a complementary prognostic tool for the management of CAP patients. They may be useful in the diagnosis, prognosis, and follow-up treatment of CAP patients, and they are also used for investigating antibiotic modifications. The most frequent biomarkers studied are C-reactive protein (CRP), procalcitonin (PCT), and cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-α.

However, IL-6 and TNF-α are used for research purposes and are not routinely assessed in clinical practice.

Measurement of PCT gives information about the severity of the disease and may help physicians to differentiate typical bacterial aetiology from atypical aetiology. A study by Johansson et al. showed that high PCT levels are related to invasive disease and pneumococcal aetiology. Higher levels of PCT are associated with bacterial pneumonia. A recent study by de Jong et al. on the efficacy and safety of PCT guidance in reducing the duration of antibiotic treatment in critically ill patients showed that PCT guidance encourages reduction of treatment duration and daily defined doses in critically ill patients with a presumed bacterial infection. This reduction was associated with a significant decrease in mortality in this population.

CRP was the pioneer biomarker and was discovered in the serum of patients with pneumococcal pneumonia. Appropriate antibiotic treatment and good outcomes have been demonstrated by decreasing levels of CRP after 3-4 days.

Several studies showed that CRP value used together with disease severity scores such as PSI or CURB65 offered predictive severity accuracy in CAP. **No part of this publication may be reproduced or photocopying without the prior written permission of the publisher. © Permanyer Publications 2017**
The study by España et al. on the utility of PCT and CRP in non-severe CAP patients showed that PCT with a cut-off point of 0.15 ng/ml was the best predictor for bacterial aetiology and for selecting patients eligible for outpatient care; levels of PCT and CRP positively correlate with increasing severity of CAP.

Pro-adrenomedullin (pro-ADM) showed a good correlation between levels of this biomarker and severity and short-term mortality in CAP studies. Several studies have suggested combining this biomarker with severity scores such as PSI and CURB-65 in order to improve the prediction of mortality and complications in CAP patients.

D-dimer: a study by Shilon et al. found a correlation between the levels of D-dimer and PSI risk class and hospital mortality in CAP patients. This study concluded that D-dimer levels at admission may predict the severity of CAP.

ASSESSMENT OF SEVERITY AND MAKING SITE-OF-CARE DECISIONS

Scoring systems such as the Pneumonia Severity Index (PSI) and CURB-65 score predict short-term mortality and were developed specifically to make the decision to admit to hospital more objective. However, these two scores are subject to certain limitations: low sensitivity and specificity for predicting the requirement for ICU admission; the inappropriate weight given to the age variable in the PSI score, which could obscure younger patients with severe disease and vice versa (not valid in children); and neither score considers factors such as psychosocial factors, infrequent comorbidities, or patient preference regarding treatment.

Recently, new severity score Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) 2007 criteria have been developed to determine ICU admission. In 2007, IDSA/ATS proposed different major and minor criteria to identify patients with severe CAP requiring ICU admission. This is based on physiological variables; in particular, minor criteria are easy to use and show high specificity (91.7%) for predicting ICU admission and need for intensive respiratory or vasopressor support. Even in the absence of major criteria, the presence of at least three minor criteria is associated with complications and a high 30-day mortality risk.

More recently, Liu et al. proposed a modified score called the expanded CURB-65, which adds three new variables to the CURB-65 score (lactic dehydrogenase > 230 µ/l, albumin < 3.5 g/dl, platelet count < 100 x 10⁹/l);
this new score is a comparatively simpler and more effective marker in assessing the severity of hospitalized patients with CAP. The expanded CURB-65 score significantly improves identification of high-risk patients by decreasing the relative weight of age and blood pressure and eliminating the use of imaging and comorbid illnesses in the calculation.

CAP is associated with long-term mortality. Several risk factors have been reported to be associated with long-term mortality for CAP, including age, cardiovascular disease, COPD, low serum albumin level at admission, diabetes, and dementia. Recent studies have focused on the relationship between CAP and cardiovascular risk as it is now known that there is link with poor outcome in patients hospitalized for CAP and also with patients after discharge. Approximately 10-30% of cardiovascular events occur in CAP patients and are related to short-term and long-term outcomes.

INTERNATIONAL GUIDELINES
RECOMMENDATION FOR ANTIMICROBIAL TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA

In general, the choice of empirical treatment is based on three main factors: CAP can be caused by many pathogens and no specific clinical presentation, laboratory data, or radiological features that distinguish each pathogen exist.

Microbiological diagnostic tests provide information hours or days after pneumonia presents. Delay in appropriate antibiotic therapy may be associated with significant mortality.

A study by Menendez et al. showed that the failure of physicians to adhere to guidelines is an independent risk factor for treatment failure and mortality in CAP cases. Tables 5, 6, and 7 summarize the recommendations of the British Thoracic Society, ATS/IDSA, and European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases guidelines.

Adjuvant therapy

Because systemic corticosteroids have broad-spectrum anti-inflammatory activity, they are
used as adjunctive therapy for CAP and several studies reported their association with a short time to clinical stability, an earlier switch to oral sequence therapy, shorter length of hospital stay, less treatment failure, and lower mortality in patients with severe CAP. However, some studies suggested that systemic corticosteroids in patients with influenza...
pneumonia are associated with increased mortality. Future studies are needed in order to determine in which cases corticosteroid therapy should be recommended.

Statin therapy is used as adjunctive therapy for CAP as some studies have shown them to have anti-inflammatory and antioxidative effects and ability to reduce cardiovascular events. Macrolides are used as adjunctive therapy for CAP because of their several immunomodulatory effects, and because they can attenuate the virulence factors of some important bacteria, such as *S. pneumoniae*, where they inhibit pneumolysin production; they also inhibit the quorum sensing by bacteria.

### Prevention

International guidelines recommend specific measures to prevent pneumonia. The most important of these is the use of pneumococcal vaccines (polysaccharide and conjugated) and influenza vaccines in all older adults and for younger persons with medical conditions that place them at high risk for pneumonia morbidity and mortality. Annual influenza vaccination is also recommended in healthcare workers, inpatient and outpatient settings, and long-term care facilities.

Since the risk of CAP is increased in current smokers, the general recommendation is to offer smoking cessation in these patients.

### Pneumococcal vaccination

Vaccination remains the primary strategy for the prevention of CAP, especially in an at-risk population (young children, the elderly, patients with comorbidities, and the immunocompromised). Two types of vaccine are currently available: polyvalent pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccines (PCV). The main difference between the types of vaccine is that PPV contains amounts (25 µg) of unconjugated purified capsular polysaccharides of each of the 23 pneumococcal serotypes, whereas in PCV, the capsular polysaccharides (2-4 µg depending on the antigen) are conjugated to a carrier protein to enhance immunogenicity. Because of the limitation of PPV23 in children, a new conjugated vaccine was developed.

Several studies assessed the effectiveness of PPV23 in CAP in the elderly. Because of the limitation of PPV23 in children and adults, a new conjugated vaccine was developed (PCV7). Despite the success of PCV7, studies have also noted an increase in the incidence of invasive pneumococcal disease (IPD) caused by non-vaccine serotypes (especially serotype 19A). A new 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13) was approved by the Food and Drug Administration (FDA) in February 2010 for the prevention of IPD in infants and young children, caused by the 13 serotypes in the vaccine. In March 2010, The Advisory Committee for Immunization Practices (ACIP) recommended that PCV13 replace PCV7 for the vaccination of children. In 2011, the FDA approved the use of PCV13 in adults aged 50 years and older for the prevention of pneumococcal pneumonia and IPD. On July 12 2016, the FDA approved expanding the indication of PCV13 vaccine to include adults 18 through 49 years of age.
A recently published randomized double-blind, placebo-controlled study (CAPiTA) was conducted in the Netherlands, involving 84,496 adults aged 65 years and over, between 2008 and 2013, to evaluate the efficacy of PPV13 vaccine in preventing the first episode of vaccine-type strains of pneumococcal CAP, non-bacteremic and noninvasive pneumococcal CAP, and IPD. The results showed 45.5% (95.2% CI; 21.8-62.5; p < 0.001) efficacy of PCV13 gains all vaccine type pneumococcal CAP, 45% (95.2% CI: 14.2-65.3; p < 0.001) efficacy against vaccine-type non-bacteremic pneumococcal CAP, and 75% (95.2% CI: 41.4-90.8; p < 0.001) efficacy against vaccine type IPD among adults aged ≥ 65 years. Due to the CAPiTA results, no new recommendations have been issued in either the US or Europe.

ADVISORY COMMITTEE FOR IMMUNIZATION PRACTICES RECOMMENDATIONS 2015 FOR PCV13 AND PPV23 IN ADULTS

- Pneumococcal vaccine in naïve persons ≥ 65 years: naïve persons should receive a single dose of PCV13 first, followed by a dose of PPV23 ≥ one year later.

- Prior vaccination with PPV23 at age ≥ 65 years: adults aged ≥ 65 years who have previously received ≥ 1 doses of PPV23 should also receive a dose of PCV13 if they have not yet received it. A dose of PCV13 should be given ≥ 1 year after receipt of the most recent PPV23 dose. In the case of patients who need repeating PPV23, the period between received PCV13 and the new dose of PPV23 should be ≥ 1 year, and five years after the most recent dose of PPV23.

- ACIP recommendations for immunocompromised patients remain unchanged.

- The recommendations for routine PCV13 use among adults aged ≥ 65 years will be re-evaluated in 2018 and revised as needed.

ADVISORY COMMITTEE FOR IMMUNIZATION PRACTICES RECOMMENDATIONS FOR PCV13 AND PPV23 IN PATIENTS AGED 19-64 YEARS WITH IMMUNOCOMPROMISED CONDITIONS OR ANATOMICAL OR FUNCTIONAL ASPLENIA, CEREBROSPINAL FLUID LEAKS OR COCHLEAR IMPLANTS

- Pneumococcal vaccine-naïve: initial dose of PCV13 followed by one dose of PPV23 (≥ 8 weeks following dose of PCV13). A second dose of PPV23 is recommended five years after the first PPV23 dose for persons aged 19-64 with immunocompromised conditions or with anatomical or functional asplenia.

- Previously vaccinated with PPV23: one dose of PCV13 (≥ 1 year after receipt of most recent PPSV23 dose) followed by one dose of PPV23 (≥ 8 weeks following dose of PCV13, and ≥ 5 years since most recent dose of PPV23).

EUROPEAN CONSIDERATION FOR PCV13 VACCINATION

In March 2015, the European Commission approved and issued indications for PCV13...
(PCV13 Summary of Product Characteristics, July 2015):

- PCV13 is indicated for active immunization for the prevention of IPD, pneumonia, and acute otitis media in infants, children, and adolescents from 6 weeks to 17 years of age;

- It is also indicated for active immunization for the prevention of IPD and pneumonia in adults ≥ 18 years of age, and the elderly.

**ON-GOING STUDIES OF NEW TREATMENTS IN COMMUNITY-ACQUIRED PNEUMONIA**

Several new antibiotics are in clinical development, with promising results for treating CAP.

**Ceftaroline fosamil**

Ceftaroline fosamil is a fifth-generation, parenteral, extended-spectrum cephalosporin that binds to penicillin-binding proteins and prevents synthesis of the bacterial cell wall. Antimicrobial activity is against gram-positive organisms, including *S. pneumoniae, Streptococcus pyogenes, S. aureus* (including MRSA, vancomycin-resistant *S. aureus* [VRSA], and hetero-resistant vancomycin intermediate *S. aureus* [hVISA]), as well as many common gram-negative organisms, such as *Haemophilus influenzae* and *Moraxella catarrhalis*.

**Ceftobiprole**

Ceftobiprole is a broad-spectrum parenteral cephalosporin and has microbiological activity against most typical bacterial pathogens that cause CAP, including MRSA.

**Nemonoxacin**

Nemonoxacin is a non-fluorinated, broad-spectrum quinolone. Nemonoxacin displayed greater activity than the fluoroquinolones (levofloxacin) against methicillin-sensitive *S. aureus*, methicillin-sensitive *Staphylococcus epidermidis* (MSSE), methicillin-resistant *S. epidermidis* (MRSE), *S. pneumoniae*, and *Enterobacter faecalis*. Interestingly, nemonoxacin maintained better activity against community-acquired MRSA than against hospital-acquired MRSA.

**Solithromycin**

Solithromycin is a novel fluoroketolide with high potency against gram-positive and gram-negative bacteria commonly associated with CAP and skin structure infections.

**Cethromycin**

Cethromycin is a new fluoroketolide with a reported high potency against gram-positive and gram-negative bacteria, and atypical pathogens (including mycoplasma and ureaplasma). It also has *in vitro* activity against penicillin-resistant and macrolide-resistant gram-positive organisms, possibly due to a high affinity for the target site on the ribosomal unit.

**CONCLUSIONS**

Community-acquired pneumonia remains a significant cause of morbidity and mortality...
worldwide despite the improved management of CAP patients. In the past 15 years, several population-based data studies on the epidemiology and microbial aetiology of CAP have been published, showing that *S. pneumoniae* (pneumococcus) is still the most frequent pathogen in CAP in all settings, in all age groups, and regardless of comorbidity. Respiratory viruses, especially influenza virus A and B, respiratory syncytial virus, and rhinovirus, are major causes of CAP. Despite the development of new molecular techniques and the implementation of diagnostic tests in CAP, more than 50% of cases remain without microbiological diagnosis. A major problem is the increased rate of antibiotic resistance of frequent pathogens in CAP and the emergence of MDR pathogens.

REFERENCES


100. Food and Drug Administration, Department Of Health And Human Services. Supplement approval. 2016.